Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), an Israel-based clinical-stage cancer immunotherapy company involved in computational target discovery, announced on Thursday that it has named Michelle Mahler MD as its new chief medical officer, effective 1 March 2024.

Mahler is to succeed Henry Adewoye, MD., who is leaving the company to pursue other opportunities effective 29 February 2024.

Mahler joined Compugen as vice president of Clinical Development. She has served as the chief medical officer of 1 E therapeutics Ltd and Aummune Therapeutics Ltd, vice president of Clinical Development at C4 Therapeutics, Inc and for nine years in R&D at Janssen (now Johnson & Johnson). She trained at Memorial Sloan Kettering Cancer Centre and New York Presbyterian Hospital/ Weill Cornell, and also spent time at Columbia Presbyterian and Mount Sinai Medical Center in New York.